A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910